Check 35,000+ stocks against 26 valuation models and 37 quality factors

SunWay Biotech Co., LTD. (1271) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of SunWay Biotech Co., LTD. TWD 64.79, price TWD 58.40, upside +10.9%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? No
Add to watchlist

Consumer Defensive · TW · ISIN TW0001271005

SB Broad data Sep 24, 2026

SunWay Biotech Co., LTD.

1271 · TWO

Low PriorityQuality growthFair Value upside is limited and quality is weak.

·Fair value 64.79 TWD · Fairly valued (+11%)

!Quality 45/100

!Mixed Growth (revenue 5y +25.9 %/yr)

✓Solidly profitable · 10.2% net margin (TTM)

✓Low debt · generates free cash flow

!Mixed vs. peers (6/14)

!Narrow moat 40/100

!Weak on past: 12 out of 100

26 models, one by oneBear 44.77 TWD to bull 103.55 TWD Growth analysisrevenue history, year by year Quality 45/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch SunWay Biotech Co., LTD. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 40.35 TWD – 133.54 TWD · fair‑value band 44.77 TWD – 103.55 TWD · the 58.40 TWD price screens below the 64.79 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow SunWay Biotech Co. in your weekly email

Every Wednesday you see whether SunWay Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. The company also researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus paracasei subsp. paracasei NTU 101; and related products. The company was founded in 2007 and is based in Taipei, Taiwan.

Stock analysis

SunWay Biotech Co., LTD. (1271) currently trades at 58.40 TWD, while our model-based Fair Value estimate is 64.79 TWD, implying the stock looks roughly 9.9% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of 77.33 TWD per share, and 4 of the 24 models we run sit above the 58.40 TWD price.

Bear case: the Economic Profit group reads lowest at 8.94 TWD, and 20 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: 44.77 TWD (bear) to 103.55 TWD (bull), the price of 58.40 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Consumer Defensive sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

SunWay Biotech Co., LTD. reported revenue of 993M TWD in FY2025 versus 380M TWD in FY2021, a compound +27.1%/yr. Reported net income was 102M TWD in FY2025, compounding −11.9%/yr from FY2021.

Key figures

Market cap 3.5B TWD (≈ $110M) · P/E ratio 34.8 · P/S ratio 3.55 · EPS (TTM) 1.68 TWD · Net margin 10.2% · Return on equity 3.1% · Return on assets (EBIT) 8.7% · Operating margin 8.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −2% fair-value upside, at 11%, 1271 screens cheaper than that median.

Fair Value models

Bear 44.77 TWD Fair Value 64.79 TWD Bull 103.55 TWD

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.23 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF 23.37 TWD 33.48 TWD 62.99 TWD 75

EPV 7.79 TWD 8.94 TWD 9.87 TWD 74

Growth DCF 21.78 TWD 36.26 TWD 58.90 TWD 74

All 24 models by family

DCF Models

FCF DCF 23.37 TWD 33.48 TWD 62.99 TWD 75

Owner Earnings 12.45 TWD 26.19 TWD 50.17 TWD 70

5Y Revenue Exit 18.06 TWD 30.71 TWD 57.05 TWD 67

5Y EBITDA Exit 25.48 TWD 45.68 TWD 85.27 TWD 69

5Y P/E Exit 24.33 TWD 54.41 TWD 95.02 TWD 65

10Y Revenue Exit 19.45 TWD 39.94 TWD 51.65 TWD 64

10Y EBITDA Exit 24.61 TWD 53.56 TWD 103.08 TWD 62

10Y P/E Exit 23.89 TWD 51.46 TWD 95.80 TWD 58

Earnings-Based

Graham-Dodd 11.49 TWD 80.11 TWD 112.42 TWD 61

Lynch FV 41.39 TWD 59.12 TWD 76.86 TWD 59

PEG = 1.0 41.39 TWD 59.12 TWD 76.86 TWD 55

EPV 7.79 TWD 8.94 TWD 9.87 TWD 74

Multiples

P/E Multiple 26.61 TWD 35.47 TWD 44.34 TWD 63

P/S Multiple 21.54 TWD 28.72 TWD 35.90 TWD 58

P/B Multiple 21.54 TWD 28.72 TWD 35.90 TWD 55

EV/EBIT 20.30 TWD 27.67 TWD 35.03 TWD 66

EV/EBITDA 26.58 TWD 36.04 TWD 45.50 TWD 67

EV/Revenue 13.98 TWD 20.73 TWD 27.49 TWD 53

Asset-Based

NCAV (Graham) 27.14 TWD 36.36 TWD 54.27 TWD 54

Growth DCF

Growth DCF 21.78 TWD 36.26 TWD 58.90 TWD 74

Rev-Margin DCF 20.00 TWD 35.39 TWD 67.67 TWD 67

Economic Profit

Residual Income 35.38 TWD 32.99 TWD 24.32 TWD 74

ROIC Compounder 7.79 TWD 8.94 TWD 9.87 TWD 70

Growth Earnings

Growth-Adj P/E 54.13 TWD 77.33 TWD 100.53 TWD 65

Open the full fair value analysis →

Notify me when 1271 reaches fair value

Put 1271 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 45/100

Of which business quality 49 · Market factors (momentum, volatility) 40

Profitability 26

Margins and returns on capital today

Quality Growth 50

Are margins and returns improving?

Cashflow 66

Earnings quality: real cash, not paper profit

Fin. Strength 75

Balance sheet, leverage, solvency risk

Investment 18

Disciplined investing over empire-building

Low Volatility 72

Calm price path (market factor)

Momentum 34

Price trend over the last 3–12 months (market factor)

52W Momentum 15

Distance to the 52-week high (market factor)

Net Issuance 43

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 95/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+2.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+32.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+25.9%

Start year 2020 (pandemic). Over 10 years: +37.7% a year

Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+38.1%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

−15.6%

Earnings growth per share plus dividend.

Earnings per share, growth per year−15.6%

Dividend (yield on the price)0.0%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 11%

Growth Forecast

Price in line with expectations

The price assumes about as much growth as the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+27.8%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +25.8% a year for the price.

Watch 1271, get fair value alerts →

Compare SunWay Biotech Co., LTD. with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 667 stocks

Beats the industry median on 6/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 45 · Below median

Fair Value upside +10% · Above median

Profitability

Return on equity (TTM) 3% · Below median

Return on assets 2% · Below median

Net margin (TTM) 10% · Top 25%

Operating margin (TTM) 9% · Above median

Growth and dividend

Revenue growth 9% · Above median

Dividend yield (TTM) 0.0% · Bottom 25%

Balance sheet

Debt / equity 0.13× · Above median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/E (TTM) 34.8× · Priciest 25%

P/B 1.09× · Cheaper than median

P/S (TTM) 3.56× · Priciest 25%

P/FCF 0.9× · Cheaper than median

EV/EBITDA 23.9× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)48 · sector 30

FUTURE (revenue growth)43 · sector 20

PAST (return on equity)12 · sector 29

HEALTH (low debt)94 · sector 96

DIVIDEND (yield)0 · sector 58

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Nestlé S.A NESN	CHF 77.09	CHF 59.49	−23%
Danone S.A BN	€60.90	€50.81	−17%
The Kraft Heinz Company KHC	$24.00	$29.20	+22%
Foshan Haitian Flavouring and Food Company 603288	¥34.29	¥37.72	+10%
Nestlé India Limited NESTLEIND	₹1,387	₹724.74	−48%
Inner Mongolia Yili Industrial Group 600887	¥26.77	¥41.84	+56%
Yihai Kerry Arawana Holdings 300999	¥25.12	¥9.98	−60%
General Mills, Inc GIS	$35.45	$34.66	−2%
Uni-President Enterprises Corp 1216	74.50 TWD	68.72 TWD	−8%
McCormick & Company MKC	$49.42	$51.01	+3%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SunWay Biotech Co., LTD. · Fair Value
64.79 TWD +10%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/1271" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">SunWay Biotech Co., LTD. · Fair Value</span><br><b style="font-size:20px">64.79 TWD</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+10%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "SunWay Biotech Co., LTD. Fair Value". https://www.fairvalue-calculator.com/stock/1271

Frequently asked questions

Is SunWay Biotech Co., LTD. (1271) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of 64.79 TWD versus a price of 58.40 TWD, about +11% upside (undervalued).

What is the fair value of 1271?

Our model-based fair value for SunWay Biotech Co., LTD. is 64.79 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 58.40 TWD.

What is the quality score of 1271?

SunWay Biotech Co., LTD. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for SunWay Biotech Co., LTD. (1271)?

Our model-based price target is the fair value of 64.79 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 44.77 TWD, optimistic scenario 103.55 TWD. It is a calculation from audited fundamentals, not an analyst target.

What is the SunWay Biotech Co., LTD. stock forecast for 2026?

Our models put fair value at 64.79 TWD, about +11% upside versus a price of 58.40 TWD (undervalued). Cautious scenario 44.77 TWD, optimistic scenario 103.55 TWD. The calculation is refreshed regularly with new filings.

What is the revenue of SunWay Biotech Co., LTD. (1271)?

SunWay Biotech Co., LTD. reported trailing-twelve-month revenue of about 993M TWD (latest available figure, as of Sep 24, 2026).

What growth is priced into SunWay Biotech Co., LTD. (1271)?

For today's price to be fair in a discounted-cash-flow model, SunWay Biotech Co., LTD. would have to grow free cash flow by +27.8 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.9 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 1271 use?

Our models discount SunWay Biotech Co., LTD. at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SunWay Biotech Co., LTD. that is +27.8 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.

How much growth has SunWay Biotech Co., LTD. (1271) delivered so far?

Over the past 5 years revenue at SunWay Biotech Co., LTD. grew +25.9 % a year. The price currently implies +27.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of SunWay Biotech Co., LTD. (1271) growing?

The median revenue growth in the sector is +2.7 % a year. That is the yardstick for the growth priced into SunWay Biotech Co., LTD. (+27.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of SunWay Biotech Co., LTD. (1271)?

The free-cash-flow yield on the price is 3.39 %: that much free cash flow SunWay Biotech Co., LTD. produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of SunWay Biotech Co., LTD. (1271)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SunWay Biotech Co., LTD. it is 64.79 TWD per share (as of Sep 24, 2026), against a price of 58.40 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is SunWay Biotech Co., LTD. stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 1271 trades below its calculated fair value: price 58.40 TWD, fair value 64.79 TWD, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 1271?

No. The price is what the market pays today (58.40 TWD); the fair value is what the company's own numbers justify (64.79 TWD). For SunWay Biotech Co., LTD. the two are 6.39 TWD per share apart. That gap is exactly why we show both numbers side by side.

How much is SunWay Biotech Co., LTD. worth?

The market values SunWay Biotech Co., LTD. at about 3.5B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 58.40 TWD; our models calculate a fair value of 64.79 TWD per share.

What do the bullish and bearish scenarios say about 1271?

Our models span a range for SunWay Biotech Co., LTD.: cautious scenario 44.77 TWD, base 64.79 TWD, optimistic 103.55 TWD per share (as of Sep 24, 2026, price 58.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 1271?

SunWay Biotech Co., LTD. trades at a price-to-earnings ratio of 34.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 64.79 TWD is built from several models across several years. Other multiples: P/B 1.1, P/S 3.6, EV/EBITDA 23.9.

How solid is the balance sheet of SunWay Biotech Co., LTD. (1271)?

Balance-sheet figures for SunWay Biotech Co., LTD. (as of Sep 24, 2026): return on equity 3.1%, debt of 0.13 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.

How far is 1271 from its 52-week high?

SunWay Biotech Co., LTD. trades at 58.40 TWD, about 23% below its 52-week high of 76.00 TWD and 13% above the low of 51.50 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 64.79 TWD is for.

Which stocks are comparable to SunWay Biotech Co., LTD.?

From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is SunWay Biotech Co., LTD. stock attractive at the current price?

The data as of Sep 24, 2026: price 58.40 TWD, calculated fair value 64.79 TWD (+11%), Quality Score 45/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 1271 calculated?

We run SunWay Biotech Co., LTD. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 64.79 TWD, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.2 % above its aggregate fair value. SunWay Biotech Co., LTD. currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of SunWay Biotech Co., LTD. (1271)?

The closing price on Sep 24, 2026 was 58.40 TWD. Our model-based fair value is 64.79 TWD, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with SunWay Biotech Co., LTD. right now?

A fairly wide model range (44.77 TWD to 103.55 TWD) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of SunWay Biotech Co., LTD.

How large is the market capitalisation of SunWay Biotech Co., LTD. (1271)?

The market capitalisation of SunWay Biotech Co., LTD. is 3.5B TWD (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of SunWay Biotech Co., LTD. (1271)?

The price-to-sales ratio of SunWay Biotech Co., LTD. is 3.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of SunWay Biotech Co., LTD. (1271)?

Earnings per share at SunWay Biotech Co., LTD. are 1.68 TWD (price ÷ EPS = P/E 34.8). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of SunWay Biotech Co., LTD. (1271)?

The net margin of SunWay Biotech Co., LTD. is 10.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of SunWay Biotech Co., LTD. (1271)?

The return on equity (ROE) of SunWay Biotech Co., LTD. is 3.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of SunWay Biotech Co., LTD. (1271)?

On an EBIT basis the return on assets of SunWay Biotech Co., LTD. is 8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of SunWay Biotech Co., LTD. (1271)?

The operating margin of SunWay Biotech Co., LTD. is 8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at SunWay Biotech Co., LTD. (1271)?

Revenue at SunWay Biotech Co., LTD. is growing +8.6% versus a year earlier (3y avg +32.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at SunWay Biotech Co., LTD. (1271)?

Earnings per share at SunWay Biotech Co., LTD. are growing +41.8% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does SunWay Biotech Co., LTD. (1271) carry?

The net debt of SunWay Biotech Co., LTD. is 358M TWD (fiscal year 2025, ≈ 3.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch SunWay Biotech Co., LTD. in the live analysis

One click puts SunWay Biotech Co., LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.